Association between full monitoring of biomedical and lifestyle target indicators and HbA1c level in primary type 2 diabetes care: an observational cohort study (ELZHA-cohort 1)

Sytske van Bruggen,1,2 Simone P Rauh,3 Marise J Kasteleyn,1 Tobias N Bonten,1 Niels H Chavannes,1 Mattijs E Numans1

ABSTRACT

Objective Management of type 2 diabetes mellitus (T2DM) requires frequent monitoring of patients. Within a collective care group setting, doubts on the clinical effects of registration are a barrier for full adoption of T2DM registration in general practice. We explored whether full monitoring of biomedical and lifestyle-related target indicators within a care group approach is associated with lower HbA1c levels.

Design Observational, real-life cohort study.
Setting Primary care data registry from the Hadoks (EerstelijnsZorggroepHaaglanden) care group.

Exposure The care group provides general practitioners collectively with organisational support to facilitate structured T2DM primary care. Patients are offered quarterly medical and lifestyle-related consultation.

Main outcome measure Full monitoring of each target indicator in patients with T2DM which includes minimally one measure of HbA1c level, systolic blood pressure, LDL, BMI, smoking behaviour and physical exercise between January and December 2014; otherwise, patients were defined as ‘incompletely monitored’. HbA1c levels of 8137 fully monitored and 3958 incompletely monitored patients were compared, adjusted for the confounders diabetes duration, age and gender. Since recommended HbA1c values depend on age, medication use and diabetes duration, analyses were stratified into three HbA1c profile groups. Linear multilevel analyses enabled adjustment for general practice.

Results Compared with incompletely monitored patients, fully monitored patients had significantly lower HbA1c levels (95% CI) in the first (−2.03 [−2.53 to −1.52] mmol/mol) (−0.19% [−0.23% to −0.14%]), second (−3.36 [−5.28 to −1.43] mmol/mol) (−0.31% [−0.48% to −0.13%]) and third HbA1c profile group (−1.89 [−3.76 to −0.01] mmol/mol) (−0.17% [−0.34% to 0.00%]).

Conclusions/interpretation This study shows that in a care group setting, fully monitored patients had significantly lower HbA1c levels compared with incompletely monitored patients. Since this difference might have considerable clinical impact in terms of T2DM-related risks, this might help general practices in care group settings to overcome barriers on adequate registration and thus improve structured T2DM primary care. From population health management perspective, we recommend a systematic approach to adjust the structured care protocol for incompletely monitored subgroups.

INTRODUCTION

Type 2 diabetes mellitus (T2DM) is a typical lifestyle-related disease.1 The course of T2DM and potential complications are influenced by smoking behaviour,2 3 BMI4 and physical exercise.5 Adopting a healthier lifestyle, for example cessation of smoking or weight loss, is known to be very demanding for individual patients.6 7 It has been established that attention for non-conscious motivational factors affecting an individual’s behaviour is important to realise sustained behavioural change.8 In addition, to avoid relapse9 10 and maintain long-term behavioural change, follow-up support for lifestyle-related themes is recommended.11 12 Accordingly, in the Netherlands, a nationally acknowledged
scientific council of general practitioners (GPs) has determined professional guidelines for diabetes primary care.\textsuperscript{15} In correspondence with the NICE guidelines,\textsuperscript{14} it is recommended to monitor HbA\textsubscript{1c} levels and also the biomedical target indicators systolic blood pressure and LDL as well as lifestyle-related indicators at least once a year.

However, for an average GP, providing structured primary diabetes care with sufficient attention for both biomedical monitoring and lifestyle adaptation\textsuperscript{15} is reported to be challenging.\textsuperscript{16} Therefore, in many Western countries, varying from the USA and Europe\textsuperscript{17} 18 to New Zealand,\textsuperscript{19} an increasing number of GPs has delegated the regular structured primary diabetes care to nurse practitioners.

It is known that implementing structured primary diabetes care and delegation of tasks to a nurse practitioner has considerable impact on the organisation of the GP practice.\textsuperscript{20} 21 For example, in the USA, an evaluation of the recent Comprehensive Primary Care (CPC) programme revealed a need to refine practice workflows, to incorporate new staff roles and to overcome incompatibility of health technology systems.\textsuperscript{22} To improve the delivery of structured primary diabetes care in the Netherlands, most GPs have joined together in local ‘care groups’.\textsuperscript{23} Care groups negotiate collective structured diabetes care protocols with the funding institutions of Dutch primary care, namely local health insurance companies. For GPs, participation in a care group is voluntary. However, the logistic and quality support to individual GP practices, which is part of the care group approach, might be seen as an incentive for care group participation. That is, the agreements between care groups and health insurance companies on structured diabetes care protocols enable GPs to offer high-quality intensive primary diabetes care.

To illustrate, on an annual basis, four consultations at the GP practice with an explicit focus on lifestyle support and quality of care are facilitated. All patients who receive diabetes care in GP practice are eligible for participation in the structured care protocol. It is known that providing a structured diabetes care protocol is associated with better monitoring of patients.\textsuperscript{24} In addition, adequate registration of the diabetes-related patient health indicators is associated with improvement of the care process.\textsuperscript{25} The costs of this protocol are fully covered by health insurance companies. For patients, participation is free of charge.

According to a recent study, care group participation is associated with improvement of the proportion of patients with full monitoring of biomedical and lifestyle-related target indicators.\textsuperscript{26} However, a review on chronic care programmes in primary care reported that doubts among care providers on the clinical effects of an intervention are a barrier for adoption.\textsuperscript{27} To our knowledge, little is known about the relationship between full monitoring of biomedical as well as lifestyle-related target diabetes indicators in a care group setting and clinical health outcomes. The HbA\textsubscript{1c} level is established as a key diabetes health indicator.\textsuperscript{28} Therefore, this study aims to investigate the association between full monitoring of biomedical and lifestyle-related diabetes target indicators and HbA\textsubscript{1c} level in patients with T2DM who receive a structured diabetes care protocol facilitated by a care group.

**RESEARCH DESIGN AND METHODS**

**Study design and population**

Data were used of T2DM patients from the observational Eerstelijns Zorggroep Haaglanden (ELZHA) cohort, which is based on primary care registry data from a care group in the western part of the Netherlands. In January 2015, the care group numbered 168 GP practices (n=24 459 patients with T2DM). On a periodical basis, GP members share an overview of their patients’ monitoring data with the care group. In February 2017, all GP practices were informed in writing and, based on an opt-out procedure, GP members were invited to participate in this cohort. For the present study, pseudonymised data on monitoring of diabetes target indicators and HbA\textsubscript{1c} levels from patients were used from the calendar year 2014. Patients receiving continuously structured primary diabetes care from January 2014 through December 2014 at the same GP practice were included. At least one registration of HbA\textsubscript{1c} in 2014 was necessary for inclusion. Since systolic blood pressure and LDL guidelines are specified for patients aged ≥80 years, patients aged ≥80 years were excluded. Patients were also excluded in case of missing data on age, gender or disease duration. Finally, since missing of data on medication use was partly caused by technical problems, patients without registration of medication prescription were also excluded.

**Exposure**

Details of the ELZHA cohort study have been described previously (Van Bruggen et al, submitted). In short, within a care group setting, GPs are able to invite all their T2DM patients with primary care treatment for this structured care protocol. During a standard diabetes consultation or at time of diagnosis, patients are informed about this care protocol. Patients who provide consent to be enrolled can join the structured primary care protocol. The protocol includes a quarterly diabetes consultation, in which diabetes-related target indicators are checked and lifestyle education is provided, combined with complementary allied health such as an annual foot check, fundus screening and dietitian’s counselling. To facilitate the organisation and quality control of this protocol, GP practices receive practical and logistical support, including a computerised system to improve the care process and outcomes. Measurement of the diabetes target indicators (HbA\textsubscript{1c} level, systolic blood pressure, LDL level, BMI, smoking behaviour and physical exercise) took place in 2014 at the end of each quarter. In the present study, patients were regarded as ‘fully monitored’
when each target indicator was registered at least once between January and December 2014. If one or more target indicators were not registered minimally one time in calendar year 2014, patients were defined as ‘incompletely monitored’.

Outcomes
The outcome of this study was HbA1c level and this was computed in two steps. First, for each quarter, a mean HbA1c value was calculated based on all available HbA1c measures in that quarter. Based on the mean HbA1c levels of all quarters, a mean was computed for the whole calendar year. HbA1c level is presented in mmol/mol and %.

Analysis
For patient’s characteristics, categorical variables were reported as numbers and percentages. Continuous variables were reported as means with SD or, when non-normally distributed, as medians with IQR. Baseline characteristics of excluded patients were, if available, compared with the study population. Linear multilevel analyses were conducted to compare HbA1c levels of fully monitored and incompletely monitored patients. Multilevel analyses allowed to adjust the individual observations (level 1) for GP practice (level 2). In addition, the analyses were adjusted for patient’s age, duration of diabetes and gender, which are relevant possible confounders with regard to HbA1c outcomes.

Tailored on specific key patient’s characteristics (age, intensity of medication treatment and disease duration), professional Dutch GP guidelines recommend differentiated HbA1c targets for three different patient profile groups based on age and prescribed medication. Details on the scientific determination of these target values are presented in the guidelines.13 To summarise, (1) for patients aged <70 years and for older patients with a mild treatment regime (only metformin monotherapy prescription or lifestyle coaching), a target HbA1c value of 53 mmol/mol (7.0 %) is recommended; (2) for patients aged ≥70 years who need more intensive treatment and were diagnosed with diabetes <10 years previously, a target HbA1c value of 58 mmol/mol (7.5 %) is recommended; (3) for patients aged ≥70 years who need more intensive treatment and were diagnosed with diabetes ≥10 years previously, a target HbA1c value of 64 mmol/mol (8.0 %) is recommended. In the present study, since missing data on medication might reflect administrative omissions rather than absence of medication treatment, patients without data on medication were excluded.

In view of the relevance for clinical practice, separate multilevel analyses were conducted and reported for each of these HbA1c profile groups. In addition, in a non-stratified multilevel analysis, we tested whether the magnitude of the effect found in HbA1c profiles 2 and 3 differed significantly from HbA1c profile 1. A p value<0.05 was considered statistically significant; for interaction, a p value<0.1 was considered statistically significant.

Descriptive statistics were analysed using SPSS, V.24.0. Multilevel analyses were performed using ML Win (V.2.28).

RESULTS
This study included 167 GP practices (99%) with a total of 24 198 patients with T2DM; of these, 12 095 patients met the inclusion criteria (for a detailed flowchart of inclusion, see figure 1). By definition, in this population, HbA1c was always monitored, as not having an HbA1c measure available was an exclusion criterion for the present study. Comparing characteristics of the excluded patients (n=12 103 patients) with the study population (n=12 095 patients, see online supplementary table 1), in excluded patients mean HbA1c level (50.32 mmol/mol, SD=12.8 mmol/mol; 6.76%, SD=3.32%, 7.535 registrations missing) was slightly lower than in the study population (52.5 mmol/mol, SD=1.07 mmol/mol; 6.95%, SD=3.16%). Comparing the median diabetes duration of excluded patients (5 years, IQR: 3–9, 63 registrations missing) to the study population (6 years, IQR: 3–10), no substantial differences were found. Regarding median age, excluded patients (71 years, IQR: 60–82, 2917 registrations missing) were older than included patients (median: 64 years, IQR: 56–71 years) and slightly more often women (50% [n=4251; 3530 registrations missing] vs 45% [n=5477]). More detailed characteristics of our study population, classified by HbA1c profile and monitoring completeness, are presented in table 1. Of patients who were incompletely monitored, information on physical exercise was most often missing, followed by smoking, BMI, LDL and systolic blood pressure (figure 2).

Compared with incompletely monitored patients, fully monitored patients had lower mean HbA1c levels in all three HbA1c profiles. In addition, fully monitored patients had a longer duration of diabetes than incompletely monitored patients.

The crude analysis showed that compared with incompletely monitored patients, the mean HbA1c of fully monitored patients was significantly lower in the first profile (−1.95 [95% CI −2.41; −1.49] mmol/mol) (−0.18% [−0.22%; −0.14%]), second profile (−2.03 [95% CI −3.41; −0.66] mmol/mol) (−0.19% [−0.31%; −0.06%]) and third profile (−1.53 [95% CI −2.96; −0.10] mmol/mol) (−0.14% [−0.27%; −0.01%]) (table 2). Multilevel
analyses with adjustment for diabetes duration, age and gender revealed similar significant associations in the first (−2.03 [95% CI −2.53; −1.52] mmol/mol) (−0.19% [−0.23%; −0.14%]), second (−3.36 [95% CI −5.28; −1.43] mmol/mol) (−0.31% [−0.48%; −0.13%]) and third profile (−1.89 [95% CI −3.76; −0.01] mmol/mol) (−0.17% [−0.34%; 0.00%]). The magnitude of these associations did not significantly differ between the HbA1c profile groups (p=0.44 and p=0.35 for the second and third profiles, respectively, compared with the first profile).
DISCUSSION

This study explored whether monitoring completeness of biomedical and lifestyle-related diabetes target indicators in a care group setting is associated with HbA1c level. In all HbA1c profile groups—defined based on patient age, intensity of medication treatment and disease duration—we found that fully monitored patients had lower HbA1c levels than incompletely monitored patients; the differences ranged from 1.89 mmol/mol (0.17 %) to 3.36 mmol/mol (0.31 %), indicating that adequate diabetes monitoring of biomedical and lifestyle indicators in primary care is associated with better HbA1c levels. To our knowledge, this is the first study to analyse the association between systematic diabetes monitoring in primary care and HbA1c levels. Apart from one longitudinal Dutch study on structured primary diabetes care in a care group setting that reported a sharp decrease in the proportion of patients with a HbA1c level ≥53 mmol/mol,24 research on absolute HbA1c differences is scarce and findings appear to be somewhat inconsistent.29–32 Therefore, caution is required when comparing our findings with any earlier studies. However, for each 1% (10.9 mmol/mol) reduction in mean HbA1c, a significant decrease in health risks has been reported, ranging from 21% for any endpoint related to diabetes including deaths to 14% for myocardial infarction and 37% for microvascular complications.33 Further, our finding that registration of physical exercise was most often lacking is in line with an earlier small-sized study in which only 19% of patients with T2DM reported ‘being guided properly’ with regard to physical exercise.34 Our finding that compared with incomplete monitoring, full monitoring of patients is associated with a lower HbA1c level might be explained by continuity of care in several ways. First, if patients are monitored at least once a year, an increasing HbA1c level might be noticed at an early stage, resulting in fast and adequate treatment. Second, periodic monitoring and coaching of patients with regard to weight loss, smoking cessation and physical exercise contributes to enduring lifestyle adaptation,11 12 which may lead to lower HbA1c levels.35

Table 1 Characteristics of the study population, classified by HbA1c profile and monitoring completeness

| HbA1c profile 1* | HbA1c profile 2† | HbA1c profile 3‡ |
|---------------------------------|---------------------------------|---------------------------------|
| **Target HbA1c:** | **Target HbA1c:** | **Target HbA1c:** |
| 53 mmol/mol (7.0%) | 58 mmol/mol (7.5%) | 64 mmol/mol (8.0%) |
| **Incomplete n=3345** | **Incomplete n=396** | **Incomplete n=217** |
| **Complete n=6794** | **Complete n=656** | **Complete n=687** |
| HbA1c level: mmol/mol mean (SD) | 53.51 (12.31) | 55.91 (11.66) | 55.12 (10.57) |
| % | 7.05 (1.13) | 7.27 (1.07) | 7.19 (0.97) |
| Diabetes duration, years: median (IQR) | 3 (3–8) | 3 (3–7) | 13 (11–16) |
| Age (years): median (IQR) | 61 (54–67) | 74 (72–76) | 74 (72–77) |
| Gender: % women (n) | 44 (1465) | 46 (183) | 51 (110) |

*Profile 1: patients aged <70 years, and older patients with a mild treatment regime (only metformin monotherapy prescription).
†Profile 2: patients aged ≥70 years who need more intensive treatment and diagnosed with diabetes <10 years ago.
‡Profile 3: patients aged ≥70 years who need more intensive treatment and diagnosed with diabetes ≥10 years ago.

Figure 2 Overview of registered indicators in incompletely monitored patients within HbA1c profile. HbA1c, Haemoglobin A1c.
Since fully monitored patients with T2DM have significantly lower HbA1c levels, their risk of any diabetes-related health complication is lower compared with incompletely monitored patients. Thus, in general, incomplete monitoring of a patient should be interpreted as an important sign of diabetes-related health risks—especially since incomplete records might be caused by no-show and also by low patient motivation, missing of prescribed lab tests and limited overall adherence to diabetes treatment. As reported by others, a tailored approach based on data registry and adjusted to patients’ characteristics (eg, monitoring completeness) is recommended. This might encourage awareness in GP practice regarding adequate diabetes management and might help GPs to overcome barriers on full adoption of the care group monitoring approach. In addition, the present findings might be relevant for other structured diabetes primary care settings that focus on frequent monitoring and adequate registration of diabetes-related health outcomes such as the CPC Plus programme in the USA.

The present study is characterised by several strengths. First, in our view, an important strength of this study is the design: although randomised clinical trials might help to eliminate bias, adequate powering and generalisability are familiar problems, whereas observational studies allow to include large study populations. For example, in this study, all patients participating in a structured primary diabetes care programme were enrolled, thereby contributing to high representativeness of our study population. Second, generally, since our study design did not interfere with the daily routine of GP practices, we assume adequate reliability of our findings. Thus, the observational real-life setting in our study reflects the reality of diabetes monitoring and HbA1c levels in primary care. Our design is in line with other studies that also used a pragmatic approach to conduct diabetes-related studies in primary care.

Third, since patients were included if they participated for at least 1 year at the same GP practice, bias caused by intermediate moving or referral to hospital diabetes care was avoided, which contributes to the stability and, thus, the validity of our findings. Finally, conducting separate analyses for each HbA1c profile group allowed adjustment for the variety in the recommended HbA1c target values.

Nevertheless, this study is also subject to some limitations that need to be mentioned. First, since no control group was included, no causal relationship between monitoring completeness and HbA1c level can be proven. Second, a missing registration does not necessarily mean that the care has not been provided. For example, missings might be caused by technical problems or lack of time for registration. Patients being considered erroneously as ‘incompletely monitored’ might have underestimated the associations found, although we did correct our analyses for age, diabetes duration, gender and GP practice.

For future research, it might be useful to analyse the context of diabetes target monitoring and explore whether the association that we found reflects a causal relationship between monitoring completeness and HbA1c level. In addition, from the GP perspective, examining potential barriers to complete monitoring, including potential benefits such as an increase of the proportion of patients with HbA1c levels within recommended values, might provide keys to improvement of the monitoring process. To ameliorate the primary diabetes care of incompletely monitored patients, exploration of their preferences and needs is suggested. In addition, an evaluation of financial costs and benefits of this care approach is recommended.

To summarise, in patients with T2DM within a care group setting, full monitoring of biomedical and lifestyle target indicators is associated with lower HbA1c levels compared with incomplete monitoring. These differences might be expected to have a considerable clinical impact in terms of diabetes-related risks. We recommend a systematic approach to analyse the needs of incompletely monitored patient groups and to adjust the structured care protocol for these subgroups in terms of population health management.

Acknowledgements The authors thank the GPs and patients of Hadoks, formerly known as the ELZHA care group for the use of their data for this study.

**Table 2** Multilevel analyses evaluating the HbA1c difference of fully monitored patients compared with incompletely monitored patients, stratified for HbA1c profile

| Profile 1 | Profile 2 | Profile 3 |
|-----------|-----------|-----------|
| B | 95% CI | P value | B | 95% CI | P value | B | 95% CI | P value |
| mmol/mol | −1.95 | −2.41 to −1.49 | <0.001 | −2.03 | −3.41 to −0.66 | 0.004 | −1.53 | −2.96 to −0.10 | 0.037 |
| % | −0.18 | −0.22 to −0.14 | <0.001 | −0.19 | −0.31 to −0.06 | 0.004 | −0.14 | −0.27 to −0.01 | 0.007 |

*Crude analysis.
†Multilevel analysis adjusted for age, diabetes duration and gender.
Contributors SvB analysed data and wrote the manuscript. SPR analysed data and reviewed the manuscript. MJK reviewed and edited the manuscript. TNB reviewed the manuscript. NHC reviewed the manuscript and contributed to the discussion. MEN is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Not required.

Ethics approval The study protocol was approved by the Medical Ethical Committee of the Leiden University Medical Center (code G16.102/Sh/sh).

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement The data that support the findings of this study are available from the corresponding author on request.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

REFERENCES
1. Howells L, Musaddaq B, McKay AJ, et al. Clinical impact of lifestyle interventions for the prevention of diabetes: an overview of systematic reviews. BMJ Open 2016;6:e013806.
2. Fagard RH. Smoking amplifies cardiovascular risk in patients with hypertension and diabetes. Diabetes Care 2009;32(Suppl 2):S249–31.
3. Qin R, Chen T, Lou Q, et al. Excess risk of mortality and cardiovascualar events associated with smoking among patients with diabetes: meta-analysis of observational prospective studies. Int J Cardiol 2013;167:342–50.
4. Gray N, Picone G, Sloan F, et al. Relation between BMI and diabetes mellitus and its complications among US older adults. South Med J 2015;108:59–55.
5. Dempsey PC, Blankenship JM, Larsen RN, et al. Interrupting prolonged sitting in type 2 diabetes: nocturnal persistence of improved glycaemic control. Diabetologia 2017;60:499–507.
6. Babb S, Malarcher A, Schauer G, et al. Quitting smoking among adults - United States, 2000-2015. MMWR Morb Mortal Wkly Rep 2017;65:1457–64.
7. Twyman L, Bonveski B, Paul C, et al. Perceived barriers to smoking cessation in selected vulnerable groups: a systematic review of the qualitative and quantitative literature. BMJ Open 2014;4:e006414.
8. Papis EK. Health goal priming as a situated intervention tool: how to benefit from nonconscious motivational routes to health behaviour. Health Psychol Rev 2016;10:408–24.
9. Arterburn DE, Bogart A, Sherwood NE, et al. A multisite study of long-term remission and relapse of type 2 diabetes mellitus following gastric bypass. Obes Surg 2013;23:93–102.
10. Hawkins J, Hollsworth W, Campbell R. Long-term smoking relapse: a study using the british household panel survey. Nicotine Tob Res 2010;12:1228–35.
11. Pjesan RJ, Muller R, Laimer M, et al. Evaluation of a multiprofessional, nonsurgical obesity treatment program: which parameters indicated life style changes and weight loss? J Eat Disord 2017;5:14.
12. Venditti EM, Wylie-Rosett J, Delahanty LM, et al. Short- and long-term lifestyle coaching approaches used to address diverse participant barriers to weight loss and physical activity adherence. Int J Behav Nutr Phys Act 2014;11:16.
13. Rutten GEH, DGW, Nijpels G, Houweling ST, et al. NHG-Standaard Diabetes mellitus type 2 (derde herziening). Huisarts en Wetenschap 2013;56:512–25.
14. National Institute for Health and Care Excellence. Type 2 diabetes in adults: management. United Kingdom: NICE guideline, 2015.
15. Ekong G, Kovvukjian J. Motivational interviewing and outcomes in adults with type 2 diabetes: a systematic review. Patient Educ Couns 2016;99:944–52.
16. Rushforth B, McCrorie C, Gidewell L, et al. Barriers to effective management of type 2 diabetes in primary care: qualitative systematic review. Br J Gen Pract 2016;66:e114–27.
17. Maier C, Aiken L, Busse R, Nurses in advanced roles in primary care: Policy levers for implementation. Paris, 2017. Report No.: 98.
18. Menghthal K, Beyer M, Gerlach FM, et al. Sharing responsibilities within the general practice team - a cross-sectional study of task delegation in Germany. PLoS One 2016;11:e0157246.
19. Hefford M, Love T, Cumming J, et al. The financial impact of clinical task substitution between practice nurses and GPs in New Zealand primary care centres. N Z Med J 2011;124:59–65.
20. Ferrante JM, Shaw EK, Bayly JE, et al. Barriers and facilitators to expanding roles of medical assistants in Patient-Centered Medical Homes (PCMHs). J Am Board Fam Med 2018;31:226–35.
21. McInnes S, Peters K, Bonney A, et al. An integrative review of facilitators and barriers influencing collaboration and teamwork between general practitioners and nurses working in general practice. J Adv Nurs 2015;71:1973–85.
22. Dale SB, Ghosh A, Peikes DN, et al. Two-year costs and quality in the comprehensive primary care initiative. N Engl J Med 2016:374:2345–56.
23. Struijs JN, Van Til JT, Baan CA. Experimenteren met de keten-dbc diabetes: de eerste zichtbare effecten. Bilthoven: RIVM; 2009:19–62.
24. Hendriks SH, van Hateren KJ, Groenier KH, et al. Sex differences in the quality of diabetes care in the Netherlands (ZODIAC-49). PLoS One 2015;10:e0145907.
25. Hoque DME, Kumar V, Hoque M, et al. Impact of clinical registries on quality of patient care and clinical outcomes: a systematic review. PLoS One 2017;12:e0183667.
26. Van Bruggen S, Kastelein MJ, Rauh SP, et al. A multidisciplinary Type 2 Diabetes Care protocol within a primary care group leads to a higher proportion of fully-monitored patients (ELZHA cohort-1). Annual Meeting, Chicago (Illinois), USA:North American Primary Care Research Group, 2018.
27. Kudlu MK, Stoile P. Barriers and facilitators of implementing the chronic care model in primary care: a systematic review. BMC Fam Pract 2015;16:12.
28. Lacey RE, Sacker A, Bell S, et al. Work-family life courses and BMI trajectories in three British birth cohorts. Int J Obes 2017;41:332–9.
29. Fuchs S, Henschke C, Blümel M, et al. Disease management programs for type 2 diabetes in Germany: a systematic literature review evaluating effectiveness. Dtsch Arztebl Int 2014;111:453–63.
30. Gabbay RA, Lendel I, Saleem TM, et al. Nurse case management improves blood pressure, emotional distress and diabetes complication screening. Diabetes Res Clin Pract 2006;71:28–35.
31. Kostev K, Rockel T, Jacob L. Impact of disease management programs on HbA1c values in type 2 diabetes patients in Germany. J Diabetes Sci Technol 2011;7:117–22.
32. Wiefen S, Kostev K, Heumann C, et al. Effect of the Disease Management Program on HbA1c value in type 2 diabetes mellitus patients: a retrospective comparison between disease management programs and standard care). Dtsch Med Wochenschr 2017;142:e148–55.
33. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;320:405–12.
34. Stuij M, Elling A, Abma TA. Conflict between diabetes guidelines and experienced counselling in sports and physical activity. An exploratory study. Eur J Public Health 2017;27:157–9.
35. Umpierre D, Ribeiro PA, Kramer CK, et al. Physical activity advice only or structured exercise training and association with HbA1c levels in type 2 diabetes: a systematic review and meta-analysis. JAMA 2011;305:1790–9.
36. Aronson R, Orzech N, Ye C, et al. Specialist-led diabetes registries and prevalence of poor glycaemic control in type 2 diabetes: the Diabetes Registry Outcomes Project for A1C Reduction (DROP A1C). Diabetes Care 2016;39:1711–7.
37. Sesums LL, McHugh SJ, Rajkumar R. Medicare’s vision for advanced primary care: new directions for care delivery and payment. JAMA 2016;315:2665–6.
38. Frakt AB. An observational study goes where randomized clinical trials have not. JAMA 2015;313:1091–2.
39. Hippisley-Cox J, Coupland C. Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care. BMJ 2016;354:i2477.
40. Prince M, Rumble R, Mares R, et al. Metabolic effects associated with ICS in patients with COPD and comorbid type 2 diabetes: a historical matched cohort study. PLoS One 2016;11:e0162903.
41. Smits KPJ, Sidorenkov G, Navis G, et al. Prescribing quality and prediction of clinical outcomes in patients with type 2 diabetes: a prospective cohort study. Diabetes Care 2017;40:e83–4.

van Bruggen S, et al. BMJ Open 2019;9:e027208. doi:10.1136/bmjopen-2018-027208